Siamak Daneshmand, MD, on next steps with TAR-200 in NMIBC

In this video, Siamak Daneshmand, MD, discusses next steps with TAR-200 in patients with non–muscle-invasive bladder cancer (NMIBC). Daneshmand presented initial safety and tolerability of this agent from the ongoing SunRISe-1 trial at the Society of Urologic Oncology 25th Annual Meeting in Dallas, Texas. Daneshmand is a professor of urology and director of clinical research at the Keck School of Medicine of the University of Southern California, Los Angeles.

Video Transcript:

Everybody wants to know about the duration of response and the complete response rates at 1 year and 2 years, and data's coming. I think it's very, very encouraging. Every time we've looked at this, the CR rates, if anything, have gone up. You see it in the 70s. Now we're seeing 85% complete response rates. [These are] highly encouraging results. Again, with that, goes to the earlier part of the conversation about the tolerability of this. We certainly want additional treatments for bladder cancer that are highly tolerable and acceptable by patients.

I've always talked about the psychological aspect of having a drug releasing system in the body that's unmeasured as of yet, where patients, I think, feel that there's something that's working all the time in their body, that they're going home with it. It's not just 1 infusion and they're done, but that rather, they're walking around, and this drug is eluding in their bladder, and it's highly efficacious. I think we can do some future studies looking at some patient's views of this vs other therapies and see if there are any differences. I think there's a lot to be done and combination therapies, other drugs that can be instilled into this device. It's a bright future.

This transcript was AI generated and edited by human editors for clarity.